BioSpace News Archive

Platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorders

The JBR Clinical Research surgical center emphasizes its dedication to safety and quality with the receipt of accreditation from the not-for-profit American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF)

Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today provided a corporate update. “Since early this year, we have continued to make great strides in advancing our clinical assets, including initiation of a pilot phase 2 for our newest clinical therapeutic, AKST1210,” said Karoly Nikolich, Ph.D., chief executive officer of Alkahest. “Whils

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael Amoroso as Senior Vice President and Chief Commercial Officer (CCO), effective immediately. Mr. Amoroso brings to Abeona over 20 years of product commercialization experience in the biotechnology and pharmaceutical industries, most recently as Senior Vice President and Head of Worldwide Commercial, Cell

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABI-H2158 (2158) for the treatment of patients with chronic HBV infection

HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) to discover and develop novel therapeutics for gout. In fewer than 18 months, HemoShear’s team has made significant progress and the company will r

Glioblastomas are the most common malignant brain tumors in adults. Treatment options are extremely limited and usually not effective, leading to death for most patients within 12-18 months of diagnosis.

Optibrium’s StarDrop™ drug discovery software inspires the next generation of high-school students in their challenge to target COVID-19

Global Biopharmaceutical Contract Development and Manufacturing Organization AGC Biologics is partnering with clinical-stage biotech company Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®.

Anteris Technologies Limited, a structural heart company advancing the DurAVR™ valve, a novel aortic valve replacement solution, announced that it will host a key opinion leader symposium on Monday, July 20, 2020 at 11:00AM EDT.